Short Interest in Synaptogenix, Inc. (NASDAQ:SNPX) Declines By 68.8%

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 5,500 shares, a drop of 68.8% from the October 15th total of 17,600 shares. Based on an average daily trading volume, of 28,400 shares, the short-interest ratio is currently 0.2 days. Currently, 0.4% of the shares of the company are sold short.

Synaptogenix Stock Up 0.3 %

SNPX traded up $0.01 on Tuesday, reaching $3.16. The stock had a trading volume of 5,305 shares, compared to its average volume of 37,914. The business’s 50-day moving average price is $3.13 and its two-hundred day moving average price is $3.85. Synaptogenix has a 12-month low of $2.72 and a 12-month high of $8.78.

Synaptogenix (NASDAQ:SNPX) last announced its earnings results on Wednesday, August 14th. The company reported ($1.18) earnings per share for the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.